Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

0.6599 -0.0001 (-0.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
A Preview Of Lexicon Pharmaceuticals's Earnings
Via Benzinga
Top 2 Health Care Stocks That May Crash This Month
Via Benzinga
Curious about the most active stocks on Monday?
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today. 
Via Chartmill
What Analysts Are Saying About Lexicon Pharmaceuticals Stock
Via Benzinga
Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket. 
Via Benzinga
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting... 
Via Benzinga
Topics Economy
Exposures Economy Interest Rates
Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Friday's session: most active stocks
Curious about the most active stocks on Friday? Find out which stocks are dominating the market action! 
Via Chartmill
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Traders are paying attention to the gapping stocks in Friday's session.
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Top movers in Friday's pre-market session
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
The company is looking for drugs it can add to Wegovy to improve the amount of weight lost. 
Via Investor's Business Daily
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected
Via Benzinga
Topics Economy
Exposures Interest Rates
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 6, 2025
Via Benzinga
Here are the top movers in Monday's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Which stocks are gapping on Monday?
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On?
Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from its PROGRESS Phase 2b study evaluating pilavapadin. 
Via Benzinga
Monday's pre-market session: top gainers and losers
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.